Seda Kafalı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seda Kafalı has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Fatih Ceylan
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
4 shared publications - Selma Tural Hesapcioglu
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
4 shared publications - Dilan Aydin Ayva
Ankara Yildirim Beyazit University Yenimahalle Education and Research Hospital
2 shared publications - Duygu Aslantaş
Ankara Yildirim Beyazit University
1 shared publication - Esra Kaygisiz
ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Mehmet Emin Şeker
Department of Stem Cell Sciences Hacettepe University Graduate School of Health Sciences Ankara Turkey
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 58 (4) , 1-6
Peripheral Nitrosative Stress in Pediatric Anxiety Disorders: Elevated Serum Nitric Oxide Levels
Background: The developing pediatric brain is vulnerable to nitrosative stress. This study investigated serum nitric oxide (NO), inducible nitric oxide synthase (iNOS), and S-nitrosothiols (SNOs) as peripheral biomarkers in children with anxiety disorders (ADs) and their associations with symptom severity. Methods: Eighty-one participants aged 7-17 years were enrolled, including 40 drug-naive participants with ADs and 41 age- and sex-matched healthy controls (HCs). Diagnoses were established using the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version, DSM-5— Turkish version (K-SADS-PL-DSM-5-T). Symptom severity was assessed using the Screen for Child Anxiety Related Emotional Disorders (SCARED) and the Clinical Global Impression–Severity (CGI-S) Scale. Data were analyzed using between-group comparisons, correlation analyses, covariance analyses (MANCOVA/ ANCOVA), controlling for age, sex, and body mass index (BMI), and receiver operating characteristic (ROC) analysis. Results: Serum NO levels were significantly higher in the AD group compared with HCs (P = .028), whereas iNOS and SNO levels did not differ (P > .05). In adjusted analyses controlling for age, sex, and BMI, NO remained significantly higher, and iNOS and SNO levels were also significantly higher in the AD group. No marker (NO, iNOS, SNOs) correlated significantly with anxiety severity (all P > .05). Receiver operating characteristic analysis indicated modest diagnostic accuracy for NO (area under the curve (AUC) = 0.629, 95% CI: 0.506-0.752, P = .046), while iNOS and SNOs were not significant. Conclusion: Elevated NO, alongside adjusted increases in iNOS and SNO, supports altered peripheral nitrosative signaling in pediatric ADs. Nitric oxide showed modest discriminative value. Cite this article as: Okuyucu M, Ceylan MF, Hesapçıoğlu ST, Kafalı S, Neşelioğlu S, Erel Ö. Peripheral nitrosative stress in pediatric anxiety disorders: elevated serum nitric oxide levels. Eurasian J Med. 2026, 58(4), 1235, doi:10.5152/eurasianjmed.2026.251235.
- 9 June 2026
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 58 (4) , 1-6
Open AccessPeripheral Nitrosative Stress in Pediatric Anxiety Disorders: Elevated Serum Nitric Oxide Levels
Background: The developing pediatric brain is vulnerable to nitrosative stress. This study investigated serum nitric oxide (NO), inducible nitric oxide synthase (iNOS), and S-nitrosothiols (SNOs) as peripheral biomarkers in children with anxiety disorders (ADs) and their associations with symptom severity. Methods: Eighty-one participants aged 7-17 years were enrolled, including 40 drug-naive participants with ADs and 41 age- and sex-matched healthy controls (HCs). Diagnoses were established using the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version, DSM-5— Turkish version (K-SADS-PL-DSM-5-T). Symptom severity was assessed using the Screen for Child Anxiety Related Emotional Disorders (SCARED) and the Clinical Global Impression–Severity (CGI-S) Scale. Data were analyzed using between-group comparisons, correlation analyses, covariance analyses (MANCOVA/ ANCOVA), controlling for age, sex, and body mass index (BMI), and receiver operating characteristic (ROC) analysis. Results: Serum NO levels were significantly higher in the AD group compared with HCs (P = .028), whereas iNOS and SNO levels did not differ (P > .05). In adjusted analyses controlling for age, sex, and BMI, NO remained significantly higher, and iNOS and SNO levels were also significantly higher in the AD group. No marker (NO, iNOS, SNOs) correlated significantly with anxiety severity (all P > .05). Receiver operating characteristic analysis indicated modest diagnostic accuracy for NO (area under the curve (AUC) = 0.629, 95% CI: 0.506-0.752, P = .046), while iNOS and SNOs were not significant. Conclusion: Elevated NO, alongside adjusted increases in iNOS and SNO, supports altered peripheral nitrosative signaling in pediatric ADs. Nitric oxide showed modest discriminative value. Cite this article as: Okuyucu M, Ceylan MF, Hesapçıoğlu ST, Kafalı S, Neşelioğlu S, Erel Ö. Peripheral nitrosative stress in pediatric anxiety disorders: elevated serum nitric oxide levels. Eurasian J Med. 2026, 58(4), 1235, doi:10.5152/eurasianjmed.2026.251235.
- Open Access
- 28 November 2025
- Published by Yildirim Beyazit University Yenimahalle Education and Research Hospital in Türk Tıp Dergisi
- Vol. 10 (4) , 129-140
The Impact of the COVID-19 Pandemic on Inpatient Psychiatric Treatment Processes in Children and Adolescents
Objective: This study aims to examine the impact of the COVID-19 pandemic on inpatient treatment processes in child and adolescent psychiatry by comparing three distinct periods: pre-pandemic, during the pandemic, and post-pandemic. Methods: Clinical data of a total of 768 patients who were hospitalized in the child and adolescent psychiatry inpatient unit of a university hospital between April 1, 2018, and January 31, 2024, were retrospectively reviewed. Sociodemographic variables (age, sex) and clinical variables (diagnosis, length of stay, number of admissions, history of suicide attempts, presence of comorbid diagnoses) were compared across three time periods. Results: During the pandemic period, a statistically significant increase was observed in the hospitalization rates of patients diagnosed with neurodevelopmental disorders, particularly attention-deficit/hyperactivity disorder (p < 0.05). Although hospitalization rates for patients diagnosed with depressive disorder, post-traumatic stress disorder, bipolar disorder, obsessive-compulsive disorder, substance use disorder, and anxiety disorders increased during the pandemic period, these increases were not statistically significant. The mean age of patients increased during the pandemic period, and the rate of comorbid diagnoses was markedly higher compared to previous periods. Additionally, the length of hospital stay was significantly shorter during the pandemic and post-pandemic periods (p < 0.05). Conclusion: The COVID-19 pandemic adversely affected the mental health of children and adolescents, particularly increasing the need for inpatient treatment among individuals with neurodevelopmental disorders. The findings highlight the necessity of maintaining the sustainability of child and adolescent mental health services world wide even under extraordinary circumstances such as a pandemic. Therefore, strengthening child mental health services and developing supportive policies targeted at vulnerable groups are crucial for preparedness in future similar crises.
- 28 November 2025
- Published by Yildirim Beyazit University Yenimahalle Education and Research Hospital in Türk Tıp Dergisi
- Vol. 10 (4) , 129-140
Open AccessThe Impact of the COVID-19 Pandemic on Inpatient Psychiatric Treatment Processes in Children and Adolescents
Objective: This study aims to examine the impact of the COVID-19 pandemic on inpatient treatment processes in child and adolescent psychiatry by comparing three distinct periods: pre-pandemic, during the pandemic, and post-pandemic. Methods: Clinical data of a total of 768 patients who were hospitalized in the child and adolescent psychiatry inpatient unit of a university hospital between April 1, 2018, and January 31, 2024, were retrospectively reviewed. Sociodemographic variables (age, sex) and clinical variables (diagnosis, length of stay, number of admissions, history of suicide attempts, presence of comorbid diagnoses) were compared across three time periods. Results: During the pandemic period, a statistically significant increase was observed in the hospitalization rates of patients diagnosed with neurodevelopmental disorders, particularly attention-deficit/hyperactivity disorder (p < 0.05). Although hospitalization rates for patients diagnosed with depressive disorder, post-traumatic stress disorder, bipolar disorder, obsessive-compulsive disorder, substance use disorder, and anxiety disorders increased during the pandemic period, these increases were not statistically significant. The mean age of patients increased during the pandemic period, and the rate of comorbid diagnoses was markedly higher compared to previous periods. Additionally, the length of hospital stay was significantly shorter during the pandemic and post-pandemic periods (p < 0.05). Conclusion: The COVID-19 pandemic adversely affected the mental health of children and adolescents, particularly increasing the need for inpatient treatment among individuals with neurodevelopmental disorders. The findings highlight the necessity of maintaining the sustainability of child and adolescent mental health services world wide even under extraordinary circumstances such as a pandemic. Therefore, strengthening child mental health services and developing supportive policies targeted at vulnerable groups are crucial for preparedness in future similar crises.
- 29 September 2025
- Published by Wiley in Stress and Health
- Vol. 41 (5) , e70109
Hsp70 and Hsp90 as Molecular Correlates of Anxiety in Children and Adolescents: The Role of Early‐Life Stress
Hsp70 and Hsp90, members of the heat shock protein family known for their cell‐protective effects against stress at the molecular level. This study aims to compare the Hsp70 and Hsp90 levels in children and adolescents with anxiety disorders and the healthy controls and to investigate the relation between Hsp70 and Hsp90 levels and the clinical parameters. The study group consisted of children and adolescents aged 8–18 who applied to the child and adolescent psychiatry outpatient clinic and were diagnosed with anxiety disorders and a healthy control group of similar age and gender. The Sociodemographic and Clinical Data Form, Screen for Child Anxiety Related Disorders, Children's Depression Inventory, and Clinical Global Impressions Scale were used. Venous blood samples were collected from the participants, and serum Hsp70 and Hsp90 levels were measured using the ELISA method. Serum levels of Hsp70 and Hsp90 were significantly lower in children and adolescents diagnosed with anxiety disorders compared to healthy controls (Hsp70: p = 0.019; Hsp90: p = 0.043). While no significant correlation was found between Hsp levels and disease severity, exposure to early‐life stress (ELS) was associated with a significant increase in Hsp70 levels overall ( p = 0.005). However, among participants exposed to ELS, those in the anxiety disorder group exhibited a markedly smaller increase in Hsp70 compared to controls with ELS exposure, suggesting a possible dysregulation of the cellular stress response in this clinical population. The results of our study indicate that psychological stress in anxiety disorders may be linked to changes in cellular stress‐related mechanisms. The reduction in serum levels of heat shock proteins, which help maintain cellular stability under stress, may contribute to the pathophysiology of anxiety disorders. However, further studies using additional cellular and molecular markers are warranted to validate these findings.
- 29 September 2025
- Published by Wiley in Stress and Health
- Vol. 41 (5) , e70109
Hsp70 and Hsp90 as Molecular Correlates of Anxiety in Children and Adolescents: The Role of Early‐Life Stress
Hsp70 and Hsp90, members of the heat shock protein family known for their cell‐protective effects against stress at the molecular level. This study aims to compare the Hsp70 and Hsp90 levels in children and adolescents with anxiety disorders and the healthy controls and to investigate the relation between Hsp70 and Hsp90 levels and the clinical parameters. The study group consisted of children and adolescents aged 8–18 who applied to the child and adolescent psychiatry outpatient clinic and were diagnosed with anxiety disorders and a healthy control group of similar age and gender. The Sociodemographic and Clinical Data Form, Screen for Child Anxiety Related Disorders, Children's Depression Inventory, and Clinical Global Impressions Scale were used. Venous blood samples were collected from the participants, and serum Hsp70 and Hsp90 levels were measured using the ELISA method. Serum levels of Hsp70 and Hsp90 were significantly lower in children and adolescents diagnosed with anxiety disorders compared to healthy controls (Hsp70: p = 0.019; Hsp90: p = 0.043). While no significant correlation was found between Hsp levels and disease severity, exposure to early‐life stress (ELS) was associated with a significant increase in Hsp70 levels overall ( p = 0.005). However, among participants exposed to ELS, those in the anxiety disorder group exhibited a markedly smaller increase in Hsp70 compared to controls with ELS exposure, suggesting a possible dysregulation of the cellular stress response in this clinical population. The results of our study indicate that psychological stress in anxiety disorders may be linked to changes in cellular stress‐related mechanisms. The reduction in serum levels of heat shock proteins, which help maintain cellular stability under stress, may contribute to the pathophysiology of anxiety disorders. However, further studies using additional cellular and molecular markers are warranted to validate these findings.
- Open Access
- 27 November 2024
- Published by Yildirim Beyazit University Yenimahalle Education and Research Hospital in Türk Tıp Dergisi
- Vol. 9 (3) , 114-125
Early Adverse Effects after COVID-19 Vaccine in Children and Adolescents with Psychiatric Disorders
Objective: Vaccines for COVID-19 have reduced the severity of the infection and prevented deaths. Parents of children on psychopharmacological medications for psychiatric disorders were also referred to the hospital to learn whether the vaccine was safe for their children. It is not known until this period how chronic psychopharmacological drug use will interact with the vaccine. This study aimed to examine the early adverse effects of COVID-19 vaccines in children and adolescents aged 12-18 who have chronic psychiatric disorders and use psychopharmacological medications. Method: Post-vaccine short-term effects of 88 patients aged 12-18, who were followed up in the child and adolescent psychiatry clinic due to chronic psychiatric disorders and were using psychopharmacological medications, were monitored and compared with 88 vaccinated healthy controls. Results: Of the 88 patients, 80 (90.9%) were vaccinated with BNT162b2 (BioNTech) as the healthy control group; 8 (9.1%) were with Sinovac. Seventy-six (86.3%) of all patients were vaccinated with the second, and 21 (24%) were with the third dose. These were 83-second and 26-third doses for the control group. From all 45.4% of the patients were using antipsychotics. The cases were examined on the fourth and seventh days after vaccination. While the most frequently reported adverse effects after the first BNT162b2 dose in the patient group on the fourth day after vaccination were local pain (58.8%), fatigue (16.3%), redness (12.5%), and headache (11.3%), side affects first Sinovac dose in the patient group were local pain (75.0%), redness (25.0%), fatigue (25.0%). There was no significant difference between the patient and control groups receiving the BNT162b2 or Sinovac vaccine regarding adverse ffects on the fourth day. At the same time, in comparisons between patients diagnosed with psychiatric disorders, no statistical difference was found in terms of early adverse effects between the patients with and without antipsychotic use. Discussion: Our study shows that the vaccines mentioned in children and adolescents with psychiatric disorders are as safe and tolerable in terms of short-term side effects as in healthy individuals. This knowledge will be crucial in guiding evidence-based clinical decision-making and ensuring the safety of children and adolescents with psychiatric disorders.
- 27 November 2024
- Published by Yildirim Beyazit University Yenimahalle Education and Research Hospital in Türk Tıp Dergisi
- Vol. 9 (3) , 114-125
Open AccessEarly Adverse Effects after COVID-19 Vaccine in Children and Adolescents with Psychiatric Disorders
Objective: Vaccines for COVID-19 have reduced the severity of the infection and prevented deaths. Parents of children on psychopharmacological medications for psychiatric disorders were also referred to the hospital to learn whether the vaccine was safe for their children. It is not known until this period how chronic psychopharmacological drug use will interact with the vaccine. This study aimed to examine the early adverse effects of COVID-19 vaccines in children and adolescents aged 12-18 who have chronic psychiatric disorders and use psychopharmacological medications. Method: Post-vaccine short-term effects of 88 patients aged 12-18, who were followed up in the child and adolescent psychiatry clinic due to chronic psychiatric disorders and were using psychopharmacological medications, were monitored and compared with 88 vaccinated healthy controls. Results: Of the 88 patients, 80 (90.9%) were vaccinated with BNT162b2 (BioNTech) as the healthy control group; 8 (9.1%) were with Sinovac. Seventy-six (86.3%) of all patients were vaccinated with the second, and 21 (24%) were with the third dose. These were 83-second and 26-third doses for the control group. From all 45.4% of the patients were using antipsychotics. The cases were examined on the fourth and seventh days after vaccination. While the most frequently reported adverse effects after the first BNT162b2 dose in the patient group on the fourth day after vaccination were local pain (58.8%), fatigue (16.3%), redness (12.5%), and headache (11.3%), side affects first Sinovac dose in the patient group were local pain (75.0%), redness (25.0%), fatigue (25.0%). There was no significant difference between the patient and control groups receiving the BNT162b2 or Sinovac vaccine regarding adverse ffects on the fourth day. At the same time, in comparisons between patients diagnosed with psychiatric disorders, no statistical difference was found in terms of early adverse effects between the patients with and without antipsychotic use. Discussion: Our study shows that the vaccines mentioned in children and adolescents with psychiatric disorders are as safe and tolerable in terms of short-term side effects as in healthy individuals. This knowledge will be crucial in guiding evidence-based clinical decision-making and ensuring the safety of children and adolescents with psychiatric disorders.